SK Biopharmaceuticals FY 2025 Annual Report
Beta

Filed: March 18, 2026· period ending December 31, 2025DART

SK Biopharmaceuticals annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 18, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).

SK Biopharmaceuticals FY 2025 Annual Report Analysis

Business Overview

• KRW 706.7B revenue in FY2025, with Cenobamate sales accounting for 96.7% (KRW 683.0B)
• AI-based epilepsy management solution commercialization via Mentis Care joint venture in 2025 recognized as revenue

Management Discussion & Analysis

• Revenue KRW 706.7B (+29% YoY), operating profit KRW 20.4B (+112%), net income KRW 25.3B (+11.5%)
• Epilepsy drug Cenobamate (XCOPRI) sales KRW 683B (96.7% of revenue), main driver of revenue growth supported by US sales and royalties

Risk Factors

• KRW ±17.1B pre-tax impact on net income for 10% USD exchange rate move in FY2025, up from KRW ±14.1B in prior year
• Foreign exchange forward contracts total USD 118M notional to hedge currency risk as of FY2025 year-end

SK Biopharmaceuticals FY 2025 Key Financial Metrics
DART

Total Assets

KRW 1.20T

▲ +15.6% YoY

Operating Cash Flow

KRW 176.3B

▲ +85.8% YoY

CapEx

KRW 6.9B

▲ +393.9% YoY

Source: KIFRS consolidated financial data from SK Biopharmaceuticals annual report on DART. All figures in KRW.

Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding